Health Care/Hospital
Happiness Biotech Group Limited Announces Name Change to Happiness Development Group Limited and Re-Designation of Its Ordinary Shares
NANPING, China, Nov. 11, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (" Happiness" or the "Company"), (NASDAQ: HAPP), is pleased to announce that effective onNovember 12, 2021, the Company will change its name to "Happiness Development Group Limited" (the "Name Change"). In addition, the ...
2021-11-11 21:00
1419
Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose
HANGZHOU, China, Nov. 11, 2021 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA106 was given to human subjects in a phase 1 study to investigate the safety, pharmacokinetics, and pharmacodynamics of this drug in the treatment of obesity. The study is a single dose, placeab...
2021-11-11 18:00
1242
Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed
* Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resistant prostate cancer (mCRPC). * Dosimetry data is be...
2021-11-10 22:06
1762
IASO Biotherapeutics and Innovent Biologics to Present New BCMA CAR-T Cell Therapy Data in Oral Presentation at ASH 2021
SAN JOSE, Calif., NANJING, China and SHANGHAI, Nov. 10, 2021 /PRNewswire/ --
IASO Biotherapeutics("IASO Bio")
2021-11-10 21:30
1649
I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa
* The partnership brings together the strengths of an innovative global biotech and a domestic leading pharmaceutical company specialized in and committed to pediatric medicines to accelerate the commercialization of eftansomatropin alfa * Jumpcan will pay I-Mab for a total of up to RMB 2.016...
2021-11-10 17:30
1750
Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting
HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a ...
2021-11-10 17:00
1497
AffaMed Therapeutics Announces the Establishment of AffaMed Digital to Advance Digital Medicines
SHANGHAI, Nov. 10, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage therapeutic company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmic, neurological and ...
2021-11-10 15:00
1889
OMRON Launches World's Fastest CT X-ray Inspection with New VT-X750-V3 AXI System
KYOTO, Japan, Nov. 10, 2021 /PRNewswire/ -- OMRON Corporation based in Kyoto, Japan, has announced the development of a new VT-X750-V3 system, the world's fastest (*1) CT-type X-ray inspection device (*2) to date, and said it will be released globally onNovember 20. The VT-X750-V3 delivers advanc...
2021-11-10 14:00
1395
Bon Natural Life Limited Announces Corporate Reorganization and Removal of VIE Structure
XI'AN, China, Nov. 9, 2021 /PRNewswire/-- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced it has removed its variable interest entity ("VIE") structure and...
2021-11-09 22:00
1721
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC
* Preclinical data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity * Both studies are undergoing phase 1 clinical trials in the United States SHANGHAI and GAITHERSBURG, Md. and SEONGNAM, South Korea, Nov. 9, 2021 /PRNewswire/ -- I-Mab ...
2021-11-09 21:05
1801
Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021
MELBOURNE, Australia, Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying vi...
2021-11-09 20:30
1457
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
SYDNEY, Nov. 9, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that an Investigational New Drug application (IND) for a trial of PXS-5505 in hepatocellular carcinoma (HCC) patients has been cleared by the United States Food and Drug Administr...
2021-11-09 19:00
1346
InnoRNA of China participates in the Hanmi Science Consortium …"To join forces to eliminate 'vaccine divide'"
SEOUL, South Korea, Nov. 9, 2021 /PRNewswire/ -- Global businesses and institutes are knocking on the door to the Hanmi Science Consortium having proprietary LNP technology. After Hanmi Science concluded a 'pandemic science alliance agreement' with theUniversity of Oxford, increasingly more entit...
2021-11-09 14:20
1526
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH
BEIJING, Nov. 9, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting onDecember 11-14, 2021, which will be hold o...
2021-11-09 13:06
1819
Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery
SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd ("SK Chemicals", KRX 285...
2021-11-09 10:47
2137
BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston
BOSTON, Nov. 5, 2021 /PRNewswire/ -- South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA therapeutics firm focused on neurodegeneration. BIORCHESTRA discovered a disease-associated microRNA that was found to be significantly up-regulated in samples from Alzheimer's disease patients. It then...
2021-11-08 22:59
2757
Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in Metastatic ER+/HER2- Breast Cancer
SUZHOU, China, and ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced a clinical trial collaborati...
2021-11-08 21:47
2187
VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onThursday, November 11, at 8:00 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2021, in addition to providin...
2021-11-08 21:30
2595
I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE
SHANGHAI and GAITHERSBURG, Md., Nov. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has entered into a strategic collaborati...
2021-11-08 21:00
1884
Farmmi Announces Latest Multi-Product Sales Win
LISHUI, China, Nov. 8, 2021 /PRNewswire/ -- Farmmi, Inc. ("Farmmi" or the "Company") (NASDAQ: FAMI), an agriculture products supplier inChina, today announced the Company's subsidiary Zhejiang Farmmi Biotechnology Co., Ltd., won a new multi-product order for its popular dried black fungus and who...
2021-11-08 21:00
1405
Week's Top Stories
Most Reposted
2024 Malaysia E-Commerce Product Selection Expo Attracts International Delegations
[Picked up by 311 media titles]
2024-12-02 12:06
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 298 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 286 media titles]
2024-11-29 20:33
Most Read
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
2024-11-29 20:33
8733
Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
2024-11-26 13:00
5188